WaferGen Gains $10.7M in Stock After Reverse-Merger With Shell Company WaferGen Bio-systems | GenomeWeb
NEW YORK (GenomeWeb News) — WaferGen has completed a reverse merger with WaferGen Bio-systems, a Nevada-based shell company, under which WaferGen backed into WaferGen Bio-systems for an undisclosed sum.  
 
In connection with the deal, the new entity, WaferGen Bio-systems, received a private stock placement worth $10.7 million. The new company’s stock is trading on the Over-the-Counter Bulletin Board under the ticker name WGBS, and was up around 15 percent at $2.30 in afternoon trading today.   
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.